External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes

被引:9
|
作者
Hubacek, J
Galbraith, PD
Gao, M
Humphries, K
Graham, MM
Knudtson, ML
Ghali, WA
机构
[1] Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada
[2] APPROACH, Calgary, AB, Canada
[3] APPROACH, Edmonton, AB, Canada
[4] Univ Alberta, Dept Med, Edmonton, AB T6G 2M7, Canada
[5] British Columbia Cardiac Registries, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.ahj.2005.04.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The recently published Michigan outcome prediction model (MM) for inhospital mortality was developed and validated on a series of consecutive patients undergoing percutaneous coronary intervention (PCI). Our purpose was to externally validate the performance of the MM in 2 separate cohorts of patients with acute coronary syndrome (ACS) undergoing PCI in Canada. Methods A validation of the MM and development of an extended MM were performed on data describing 10050 patients from the APPROACH prospective cohort study between January 1995 and December 2000. Performance of both models was assessed on an external data set of 3259 PCI cases from the British Columbia Cardiac Registries. Only patients with a diagnosis of ACS were included in the study. Results The original MM predicted death rates ranging from 0.1% to 60.6%, but lacked accuracy to predict inhospital mortality as severity increased. The extended MM predicted death rates more widely from 0.0% to a high of 91.0% with better accuracy to predict inhospital death in patients with ACS undergoing PCI. The areas under the receiver operating characteristic curve for the MM and the extended MM on the external validation data set were 0.93. and 0.95, respectively. Conclusion The MM predicts death after PCI in patients with ACS and identifies a clear gradient of risk. However, the enhanced MM developed specifically for the subset of patients with ACS demonstrated better prediction and cross-validated performance. These prediction rules can be useful for risk-adjustment analyses and for prognostication for individual patients.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 50 条
  • [21] Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Saborido, C. M.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Dickson, R.
    Proudlove, C.
    Kolamunnage-Dona, R.
    Fisher, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 31 - 38
  • [22] Impact of Multivessel Percutaneous Coronary Intervention vs. Culprit Vessel Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes and Multivessel Coronary Artery Disease
    Yasuda, Kentaro
    Ogita, Manabu
    Tsuboi, Shuta
    Nishio, Ryota
    Takeuchi, Mitsuhiro
    Sonoda, Taketo
    Wada, Hideki
    Suwa, Satoru
    Miyauchi, Katsumi
    Daida, Hiroyuki
    Minamino, Tohru
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2023, 53 : 38 - 44
  • [23] Association of left ventricular end-diastolic pressure with mortality in patients undergoing percutaneous coronary intervention for acute coronary syndromes
    Leistner, David M.
    Dietrich, Steven
    Erbay, Aslihan
    Steiner, Julia
    Abdelwahed, Youssef
    Siegrist, Patrick T.
    Schindler, Matthias
    Skurk, Carsten
    Haghikia, Arash
    Sinning, David
    Riedel, Matthias
    Landmesser, Ulf
    Staehli, Barbara E.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2020, 96 (04) : E439 - E446
  • [24] Outcomes of Patients With Acute Coronary Syndromes Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention
    Simsek, Bahadir
    Kostantinis, Spyridon
    Md, Judit Karacsonyi
    Gorgulu, Sevket
    Alaswad, Khaldoon
    Md, Farouc A. Jaffer
    Doshi, Darshan
    Khatri, Jaikirshan
    Poommipanit, Paul
    Aygul, Nazif
    Rafeh, Nidal Abi
    Krestyaninov, Oleg
    Khelimskii, Dmitrii
    Uretsky, Barry
    Davies, Rhian
    Goktekin, Omer
    ElGuindy, Ahmed
    Jefferson, Brian K.
    Patel, Taral N.
    Patel, Mitul
    Mastrodemos, Olga C.
    Rangan, Bavana V.
    Allana, Salman
    Sandoval, Yader
    Burke, M. Nicholas
    Brilakis, Emmanouil S.
    JOURNAL OF INVASIVE CARDIOLOGY, 2023, 35 (01): : E24 - E30
  • [25] Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
    De Luca, Leonardo
    Mistrulli, Raffaella
    Veneziano, Francesco Antonio
    Grigioni, Francesco
    Volpe, Massimo
    Musumeci, Francesco
    Gabrielli, Domenico
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (03)
  • [26] Prasugrel A Review of its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
    Duggan, Sean T.
    Keating, Gillian M.
    DRUGS, 2009, 69 (12) : 1707 - 1726
  • [27] Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Parikh, Shailja V.
    Keeley, Ellen C.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 677 - 691
  • [28] Intensity of Antiplatelet Therapy in Patients with Acute Coronary Syndromes and Percutaneous Coronary Intervention: the Promise of Prasugrel?
    Wiviott, Stephen D.
    CARDIOLOGY CLINICS, 2008, 26 (04) : 629 - +
  • [29] BIVALIRUDIN VERSUS UNFRACTIONED HEPARIN IN PATIENTS RECEIVING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES
    Farag, Mohamed
    Gorog, Diana
    Srinivasan, Manivannan
    HEART, 2015, 101 : A9 - A9
  • [30] PrasugrelA Review of its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
    Sean T. Duggan
    Gillian M. Keating
    Drugs, 2009, 69 : 1707 - 1726